{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:29Z","timestamp":1790805149005,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ymgmr.2020.100583","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:53:45Z","timestamp":1588294425000},"page":"100583","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort"],"prefix":"10.1016","volume":"23","author":[{"given":"Monique","family":"Piraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Pettazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"de Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Vianey-Saban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"Froissart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Chabrol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Lafor\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2020.100583_bb0005","first-page":"96","article-title":"Progress and problems in muscle glycogenoses","volume":"30","author":"Di Mauro","year":"2011","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"alpha-Glucosidase deficiency in generalized glycogen storage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"issue":"5","key":"10.1016\/j.ymgmr.2020.100583_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"Infantile-onset Pompe disease natural history study group. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"Pt 3","key":"10.1016\/j.ymgmr.2020.100583_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","article-title":"Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study","volume":"41","author":"Semplicini","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgmr.2020.100583_bb0030","doi-asserted-by":"crossref","DOI":"10.1136\/bmjpo-2017-000182","article-title":"Incidence of infantile Pompe disease in the Maroon population of French Guiana","volume":"9","author":"Elenga","year":"2018","journal-title":"BMJ Paediatr. Open."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0035","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10545-011-9360-2","article-title":"Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases","volume":"35","author":"Manwaring","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0040","first-page":"67","article-title":"Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening","volume":"19","author":"Chien","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0045","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0050","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/nar\/gkt987","article-title":"Functional characterization of the common c.-32-13T>G mutation of GAA gene: Identification of potential therapeutic agents","volume":"42","author":"Dardis","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100583_bb0065","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: Improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics."},{"issue":"16","key":"10.1016\/j.ymgmr.2020.100583_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94328","article-title":"Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease","volume":"2","author":"Kazi","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymgmr.2020.100583_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.ymgmr.2020.100583_bb0080","doi-asserted-by":"crossref","first-page":"9462","DOI":"10.1021\/acs.jmedchem.7b00646","article-title":"N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an allosteric enhancer of \u03b1-glucosidase activity for the treatment of Pompe disease","volume":"60","author":"D\u2019Alonzo","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2362.1974.tb00416.x","article-title":"Increased excretion of a glucose-containing tetrasaccharide in the urine of a patient with glycogen storage disease type II (Pompe\u2019s disease)","volume":"4","author":"Hallgren","year":"1974","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0090","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0021-9258(19)75202-8","article-title":"Quantitation of some urinary oligosaccharides during pregnancy and lactation","volume":"252","author":"Hallgren","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0095","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/bms.1200030202","article-title":"Quantitation of a urinary tetrasaccharide by gas chromatography and mass spectrometry","volume":"3","author":"Lennartson","year":"1976","journal-title":"Biomed. Mass Spectrom."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0003-2697(03)00056-3","article-title":"Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry","volume":"316","author":"Young","year":"2003","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0105","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajmg.c.31320","article-title":"Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques","volume":"160C","author":"Young","year":"2012","journal-title":"Am. J. Med. Genet. C Semin. Med. Genet."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/GIM.0b013e3181a87867","article-title":"Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker","volume":"11","author":"Young","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/abio.2000.4838","article-title":"Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease","volume":"287","author":"An","year":"2000","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2005.03.010","article-title":"Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease","volume":"85","author":"An","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/clinchem\/48.1.131","article-title":"Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry","volume":"48","author":"Rozaklis","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1373\/clinchem.2011.178319","article-title":"Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases","volume":"58","author":"Sluiter","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0135","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: Enzymatic screening in dried blood spots on filter paper","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2020.100583_bb0140","first-page":"450","article-title":"A fluorometric assay of alpha-glucosidase and its application in the study of Pompe\u2019s disease","volume":"81","author":"Salafsky","year":"1973","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0145","first-page":"659","article-title":"Immunochemical study of acid alpha-1,4-glucosidase in 7 patients with type II glycogenosis","volume":"34","author":"Bienvenu","year":"1979","journal-title":"P\u00e9diatrie."},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100583_bb0150","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1002\/humu.20745","article-title":"Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating","volume":"29","author":"Kroos","year":"2008","journal-title":"Hum. Mutat."},{"issue":"14","key":"10.1016\/j.ymgmr.2020.100583_bb0155","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1016\/S0021-9258(17)34648-3","article-title":"The apparent activity in vivo of the lysosomal pathway of glycogen catabolism in cultured human skin fibroblasts from patients with type III glycogen storage disease","volume":"253","author":"Brown","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0160","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s10545-016-9932-2","article-title":"Glycogen storage disease type III: Diagnosis, genotype, management, clinical course and outcome","volume":"39","author":"Sentner","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0165","first-page":"1","article-title":"Glycogen storage disease","volume":"13","author":"Hers","year":"1964","journal-title":"Adv. Metab. Disord."},{"issue":"6","key":"10.1016\/j.ymgmr.2020.100583_bb0170","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in the Netherlands: Implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur. J. Hum. Genet."},{"issue":"536(7616)","key":"10.1016\/j.ymgmr.2020.100583_bb0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"18","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymgmr.2020.100583_bb0180","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1542\/peds.27.1.103","article-title":"Glycogen in erythrocytes of patients with glycogen storage disease","volume":"27","author":"Sidbury","year":"1961","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2020.100583_bb0185","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0009-9120(91)90511-C","article-title":"Biochemical diagnosis of hepatic glycogen storage diseases: 20 years French experience","volume":"24","author":"Maire","year":"1991","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0190","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymgme.2011.05.010","article-title":"Liver glycogen storage diseases due to phosphorylase system deficiencies: Diagnosis thanks to non invasive blood enzymatic and molecular studies","volume":"104","author":"Davit-Spraul","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-019-0561-7","article-title":"Liver fibrosis during clinical ascertainment of glycogen storage disease type III: A need for improved and systematic monitoring","author":"Halaby","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2020.100583_bb0200","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s10545-005-0095-9","article-title":"Biochemical characteristics and increased tetraglucoside excretion in patients with phosphorylase kinase deficiency","volume":"28","author":"Morava","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgmr.2020.100583_bb0205","first-page":"460","article-title":"Urinary glucose tetrasaccharide: A useful prognostic biomarker for Pompe disease?","volume":"42","author":"Prunty","year":"2019","journal-title":"J. Inherit. Metab. Dis"}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692030029X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221442692030029X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:50:58Z","timestamp":1762001458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221442692030029X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":41,"alternative-id":["S221442692030029X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100583","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2020.100583","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100583"}}